-
公开(公告)号:US20230112220A1
公开(公告)日:2023-04-13
申请号:US17904816
申请日:2021-02-26
申请人: VERONA PHARMA PLC
IPC分类号: A61K31/519 , A61K31/40 , A61K9/00 , A61K47/12 , A61K47/02
摘要: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg/mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.
-
公开(公告)号:US10945950B2
公开(公告)日:2021-03-16
申请号:US15927517
申请日:2018-03-21
申请人: VERONA PHARMA PLC
IPC分类号: A61K9/00 , A61K31/495 , A61K31/519 , A61K47/02 , A61K47/26
摘要: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.
-
公开(公告)号:US10710998B2
公开(公告)日:2020-07-14
申请号:US16309435
申请日:2017-07-27
申请人: VERONA PHARMA PLC
发明人: Peter Lionel Spargo
IPC分类号: C07D471/04
摘要: The present invention relates to a novel nitrile derivative of a pyrimido[6,1-a]isoquinolin-4-one compound of formula (A). The invention further relates to a process for producing a compound of formula (A). The invention also relates to a process which comprises reducing a compound of formula (A). Compounds of the invention are useful in the production of compounds such as RPL554.
-
4.
公开(公告)号:US20130225616A1
公开(公告)日:2013-08-29
申请号:US13814877
申请日:2011-08-09
IPC分类号: C07D471/04 , A61K45/06 , A61K31/519
CPC分类号: C07D471/04 , A61K31/519 , A61K45/06
摘要: The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.
摘要翻译: 本发明涉及N- {2 - [(2E)-2-(甲基咪唑基)-9,10-二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a ] - 异喹啉-3(4H) - 基]乙基}脲,其结晶固体形式由大于99重量%的N- {2 - [(2E)-2-(甲基咪唑基)-9,10 - 二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a]异喹啉-3(4H) - 基]乙基}脲,多晶型物的热力学稳定多晶型物的至少95% (I)N- {2 - [(2E)-2-(甲基咪唑基)-9,10-二甲氧基-4-氧代-6,7-二氢-2H-嘧啶并[6,1-a] - 异喹啉-3 (4H) - 基]乙基}脲,其中所述多晶型物通过单晶X射线结构分析和X射线粉末衍射图确定。
-
公开(公告)号:US20080206163A1
公开(公告)日:2008-08-28
申请号:US12150232
申请日:2008-04-24
IPC分类号: A61K9/12 , C07D471/04 , A61K31/519
CPC分类号: C07D471/04
摘要: Compounds of general formula (I) wherein each of R1 and R2 independently represents a C1-6 alkyl or C2-7 acyl group; R5 represents a hydrogen atom or a C1-3 alkyl, C2-3 alkenyl or C2-3 alkynyl group; R6 represents a hydrogen atom or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, amino, C1-6 alkylamino, di(C1-6) alkylamino or C2-7 acylamino group; each of R7 and R8 independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-7 acyl, C1-6 alkythio, C1-6 alkoxy, C3-6 cycloalkyl; and R9 represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-7 acyl, C1-6 alkythio, C1-6 alkoxy or C3-6 cycloalkyl group; X represents OCH2 or a group CR3R4, wherein each of R3 and R4 independently represents a hydrogen atom or a C1-3 alkyl group; each of R10 and R11 independently represents a hydrogen atom, a C1-3 alkyl, C3-6 cycloalkyl or phenyl group; y represents an oxygen atom or a group CHNO2, NCN, NH or NNO2, n is an integer from 2 to 4; or a salt thereof; are useful for treatment of respiratory disorders such as asthma. Compounds of the invention have a longer duration of action than the known compound trequinsin (9,10-dimethoxy-3-methyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one) and do not have trequinsin's very bitter taste.
-
公开(公告)号:US11491155B2
公开(公告)日:2022-11-08
申请号:US16580515
申请日:2019-09-24
申请人: VERONA PHARMA PLC
IPC分类号: A61K31/513 , C07D471/04 , A61K9/00 , A61K31/185 , A61K31/519 , A61K45/06
摘要: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
-
公开(公告)号:US10471063B2
公开(公告)日:2019-11-12
申请号:US15614440
申请日:2017-06-05
申请人: VERONA PHARMA PLC
IPC分类号: A61K31/519 , A61K31/40 , A61K45/06 , A61K9/00 , A61K31/137 , A61K31/167 , A61K31/44 , A61K31/46 , A61K9/48 , A61M15/00
摘要: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.
-
公开(公告)号:US09717732B2
公开(公告)日:2017-08-01
申请号:US14771097
申请日:2014-03-17
申请人: VERONA PHARMA PLC
IPC分类号: A61K31/505 , A61K31/519 , A61K31/40 , A61K45/06 , A61K9/00 , A61K31/137 , A61K31/167 , A61K31/44 , A61K31/46 , A61K9/48 , A61M15/00
CPC分类号: A61K31/519 , A61K9/0075 , A61K9/0078 , A61K9/008 , A61K9/0095 , A61K9/4858 , A61K31/137 , A61K31/167 , A61K31/40 , A61K31/44 , A61K31/46 , A61K45/06 , A61M15/009 , A61M2202/064 , A61K2300/00
摘要: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a β2-adrenergic receptor agonist.
-
公开(公告)号:US20120302533A1
公开(公告)日:2012-11-29
申请号:US13568754
申请日:2012-08-07
IPC分类号: A61K31/519 , A61P11/08 , A61P29/00 , A61K31/56
CPC分类号: C07D471/04
摘要: The present invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their application as inhibitors of phosphodiesterase (PDE) isoenzymes. More particularly the invention relates to derivatives of pyrimido[6,1-a]isoquinolin-4-one and their use in medicine for example as bronchodilators with anti-inflammatory properties.
摘要翻译: 本发明涉及嘧啶并[6,1-a]异喹啉-4-酮的衍生物及其作为磷酸二酯酶(PDE)同功酶抑制剂的应用。 更具体地,本发明涉及嘧啶并[6,1-a]异喹啉-4-酮的衍生物及其在医学中的用途,例如具有抗炎性质的支气管扩张剂。
-
10.
公开(公告)号:US20210379053A1
公开(公告)日:2021-12-09
申请号:US17280452
申请日:2019-10-09
申请人: VERONA PHARMA PLC
IPC分类号: A61K31/4745 , A61K9/00 , A61K47/06
摘要: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) a suspension of particles comprising 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) a diluent which is 1,1,1,2-tetrafluoroethane (HFA-134a), wherein the liquid pharmaceutical composition is substantially free of surfactant. The invention also relates to a pressurised metered dose inhaler comprising the liquid pharmaceutical composition.
-
-
-
-
-
-
-
-
-